Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1989 2
1990 3
1991 1
1992 5
1993 2
1994 3
1995 4
1996 7
1997 5
1998 5
1999 2
2000 3
2001 8
2002 12
2003 11
2004 25
2005 9
2006 6
2007 10
2008 16
2009 30
2010 50
2011 60
2012 60
2013 101
2014 203
2015 208
2016 263
2017 270
2018 273
2019 276
2020 347
2021 423
2022 391
2023 497
2024 231

Text availability

Article attribute

Article type

Publication date

Search Results

3,485 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for eli broad
Your search for Elin Brodd retrieved no results
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.
Lingvay I, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lincoff AM, Marso SP, Fries TM, Plutzky J, Ryan DH; SELECT Study Group. Lingvay I, et al. Obesity (Silver Spring). 2023 Jan;31(1):111-122. doi: 10.1002/oby.23621. Epub 2022 Dec 10. Obesity (Silver Spring). 2023. PMID: 36502289 Free PMC article. Clinical Trial.
CONCLUSIONS: The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups....
CONCLUSIONS: The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allo …
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ, McIntosh D, Milev RV, Müller DJ, Parikh SV, Pearson NL, Ravindran AV, Uher R; CANMAT Depression Work Group. Kennedy SH, et al. Can J Psychiatry. 2016 Sep;61(9):540-60. doi: 10.1177/0706743716659417. Epub 2016 Aug 2. Can J Psychiatry. 2016. PMID: 27486148 Free PMC article. Review.
RESULTS: Evidence-informed responses are given for 21 questions under 4 broad categories: 1) principles of pharmacological management, including individualized assessment of patient and medication factors for antidepressant selection, regular and frequent monitoring, and a …
RESULTS: Evidence-informed responses are given for 21 questions under 4 broad categories: 1) principles of pharmacological management …
Ensembles of endothelial and mural cells promote angiogenesis in prenatal human brain.
Crouch EE, Bhaduri A, Andrews MG, Cebrian-Silla A, Diafos LN, Birrueta JO, Wedderburn-Pugh K, Valenzuela EJ, Bennett NK, Eze UC, Sandoval-Espinosa C, Chen J, Mora C, Ross JM, Howard CE, Gonzalez-Granero S, Lozano JF, Vento M, Haeussler M, Paredes MF, Nakamura K, Garcia-Verdugo JM, Alvarez-Buylla A, Kriegstein AR, Huang EJ. Crouch EE, et al. Cell. 2022 Sep 29;185(20):3753-3769.e18. doi: 10.1016/j.cell.2022.09.004. Cell. 2022. PMID: 36179668 Free PMC article.
Development and Arealization of the Cerebral Cortex.
Cadwell CR, Bhaduri A, Mostajo-Radji MA, Keefe MG, Nowakowski TJ. Cadwell CR, et al. Neuron. 2019 Sep 25;103(6):980-1004. doi: 10.1016/j.neuron.2019.07.009. Neuron. 2019. PMID: 31557462 Free PMC article. Review.
We propose an integrated model of serial homology whereby intrinsic genetic programs and local factors establish early transcriptomic differences between excitatory neurons destined to give rise to broad "proto-regions," and activity-dependent mechanisms lead to progressiv …
We propose an integrated model of serial homology whereby intrinsic genetic programs and local factors establish early transcriptomic differ …
Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations.
Butala S, Castelo-Soccio L, Seshadri R, Simpson EL, O'Shea JJ, Bieber T, Paller AS. Butala S, et al. J Allergy Clin Immunol Pract. 2023 May;11(5):1361-1373. doi: 10.1016/j.jaip.2023.03.011. Epub 2023 Mar 21. J Allergy Clin Immunol Pract. 2023. PMID: 36948491 Free PMC article. Review.
Food and Drug Administration approval of dupilumab for moderate-to-severe atopic dermatitis shifted the paradigm from use of broad, systemic immunosuppressants to a safer, targeted treatment and led to the emergence of newer interleukin (IL)-4/IL-13 directed biologics and …
Food and Drug Administration approval of dupilumab for moderate-to-severe atopic dermatitis shifted the paradigm from use of broad, s …
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D'Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW. Willard FS, et al. JCI Insight. 2020 Sep 3;5(17):e140532. doi: 10.1172/jci.insight.140532. JCI Insight. 2020. PMID: 32730231 Free PMC article.
Therefore, we hypothesized that the integrated potency and signaling properties of tirzepatide provide a unique pharmacological profile tailored for improving broad metabolic control. Here, we establish methodology for calculating occupancy of each receptor for clinically …
Therefore, we hypothesized that the integrated potency and signaling properties of tirzepatide provide a unique pharmacological profile tail …
Defining Transcriptional Signatures of Human Hair Follicle Cell States.
Takahashi R, Grzenda A, Allison TF, Rawnsley J, Balin SJ, Sabri S, Plath K, Lowry WE. Takahashi R, et al. J Invest Dermatol. 2020 Apr;140(4):764-773.e4. doi: 10.1016/j.jid.2019.07.726. Epub 2019 Oct 31. J Invest Dermatol. 2020. PMID: 31676413 Free PMC article. Review.
Immune-mediated inflammatory disease therapeutics: past, present and future.
McInnes IB, Gravallese EM. McInnes IB, et al. Nat Rev Immunol. 2021 Oct;21(10):680-686. doi: 10.1038/s41577-021-00603-1. Epub 2021 Sep 13. Nat Rev Immunol. 2021. PMID: 34518662 Free PMC article. Review.
Although they are currently incurable, the therapeutic armamentarium for immune-mediated inflammatory diseases has been transformed in the past two decades. We have moved from the wide application of broad-spectrum immune modulators to the routine use of agents with exquis …
Although they are currently incurable, the therapeutic armamentarium for immune-mediated inflammatory diseases has been transformed in the p …
3,485 results